FDA Approves Foundayo: A New Oral GLP-1 Weight Loss Drug
Key Takeaways
- Clinically Meaningful Weight Loss: In its pivotal Phase 3 trial, the highest dose of Foundayo (36 mg) led to an average weight loss of 11.2% to 12.4% of body weight over 72 weeks, compared to just 2.1% with placebo.
- First-in-Class Oral Pill: Foundayo (orforglipron) is the first FDA-approved oral, non-peptide, small-molecule GLP-1 receptor agonist. This unique structure allows it to be taken as a simple once-daily pill without the strict fasting or water restrictions required for other oral GLP-1s.
- Approved Patient Population: The FDA has approved Foundayo for adults with obesity (BMI ≥30) or those who are overweight (BMI ≥27) and have at least one weight-related condition like high blood pressure or high cholesterol.
- Consistent Safety Profile: The most common side effects are gastrointestinal, including nausea (affecting 29-36% of users), diarrhea, and vomiting, which is consistent with the established safety profile of the GLP-1 receptor agonist class.
Obesity medicine just got a major shake-up today with the U.S. Food and Drug Administration’s approval of Foundayo (orforglipron). Eli Lilly developed this drug. And this is a big deal because Foundayo is now the first-ever oral, small-molecule GLP-1 receptor agonist available for chronic weight management. For years, our most effective medical treatments for obesity have been injectables. Existing oral options have always had their downsides. But the approval of the Foundayo weight loss drug introduces a highly anticipated once-daily pill that sidesteps many of these barriers. So, what’s this all about? I’ll break down the FDA’s decision, we’ll look at the clinical data from the ATTAIN-1 trial, explain who can get this new treatment, and talk about where Foundayo fits in our ever-growing toolbox for fighting obesity.
A New Era for Oral Obesity Treatment: What is Foundayo?
Foundayo (orforglipron) is a huge scientific leap in the GLP-1 receptor agonist (RA) class. Unlike existing GLP-1 drugs such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound), which are peptides, Foundayo is a non-peptide, small-molecule drug. This chemical difference? It’s key. Peptides are large molecules. Your stomach acid usually breaks them down. That’s why we inject them, or for oral semaglutide, we have to use special absorption enhancers and insist on those strict fasting rules (like waiting at least 30 minutes before any food, drink, or other medications).
But Foundayo’s small-molecule structure means it can stand up to your digestive system. This gives it true oral bioavailability, no more annoying restrictions. Patients can just pop this once-daily pill, food or no food. That convenience could really help people stick with their treatment, making it so much easier. This breakthrough simplifies things. It makes GLP-1 therapy, with all its powerful effects, much more accessible to many more patients. Foundayo works by activating the GLP-1 receptor. It mimics natural incretin hormones, which help regulate appetite, slow stomach emptying, and improve blood sugar control—and all these things together lead to eating less and losing real weight.
FDA-Approved Indication: Who is a Candidate for Foundayo?
The FDA approved Foundayo for a very specific group of patients. It reminds us: this is a real medical treatment for a chronic disease, not just something for looks. The official word is this: Foundayo is for chronic weight management. It’s meant to be used alongside a reduced-calorie diet and more physical activity. It’s for adults who have:
- An initial Body Mass Index (BMI) of 30 kg/m² or greater (obesity), or
- An initial BMI of 27 kg/m² or greater (overweight) and at least one weight-related comorbid condition.
These weight-related conditions include common problems. Think high blood pressure (hypertension), high cholesterol or triglycerides (dyslipidemia), obstructive sleep apnea (OSA), or established heart disease. But like any medication in this class, there are important reasons not to use it. If you or your family have a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), Foundayo is a no-go. And it’s definitely not for pregnant patients. In my clinical experience, we’ll be extra careful prescribing it if a patient has had pancreatitis or gallbladder disease. Those are known risks with GLP-1s.
Clinical Efficacy: A Deep Dive into the ATTAIN-1 Trial Data
The FDA gave the green light for the Foundayo weight loss drug because of the really strong results from the Phase 3 ATTAIN-1 clinical trial. It was published in the New England Journal of Medicine, too. This was a 72-week study. It included 3,127 adults who were obese or overweight, but didn’t have diabetes. The results showed weight loss that depended on the dose, and it was clinically significant.
At the highest approved dose of 36 mg daily, participants taking Foundayo achieved a mean body weight reduction between 11.2% and 12.4% from baseline. Now, compare that to the placebo group, who only lost 2.1% even with diet and exercise coaching. The data on ‘responder rates’—that’s the percentage of patients hitting certain weight loss goals—is what really catches my eye. On the 36 mg dose, about 55-60% of people lost at least 10% of their body weight. That’s a target we consider truly meaningful for heart and metabolic health. And 36-40% of participants hit at least 15% weight loss. What’s even more impressive? 19% lost 20% or more. Those numbers were way, way higher than the placebo group. Only 13%, 6%, and 3% of them reached those same milestones.
But it wasn’t just about weight. Foundayo also brought big improvements in other important health markers. Patients’ waistlines shrunk by an average of 10 cm. Their systolic blood pressure dropped by 5 to 6 mmHg, too. We also saw big reductions in triglycerides, non-HDL cholesterol, and LDL cholesterol.
Safety, Tolerability, and Side Effects
Let’s be real: no medication is perfect. Foundayo has potential side effects, but its safety profile is exactly what we’ve come to expect from the GLP-1 receptor agonist class. The ATTAIN-1 trial didn’t show anything new or surprising on the safety front. Most of the side effects were tummy troubles. Nausea was the big one. It hit 29-36% of participants taking the drug, versus about 10% in the placebo group. Other common ones included diarrhea, vomiting, belly discomfort, and just not feeling hungry. These are usually mild to moderate. And often, they get better as your body gets used to the medication. We use a gradual dose increase schedule, precisely to help ease these initial side effects.
How many people stopped
Sources
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine, 2025. PMID: 40960239. doi:10.1056/NEJMoa2511774
- Santulli G. From needles to pills: oral GLP-1 therapy enters the obesity arena. Cardiovascular Diabetology Endocrinology Reports, 2025. PMID: 41053816. doi:10.1186/s40842-025-00245-5
- Xie Z, Zheng G, Liang Z, et al. Seven GLP-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism, 2024. PMID: 39305981. doi:10.1016/j.metabol.2024.156038
- Kokkorakis M, Chakhtoura M, Rhayem C, et al. Emerging pharmacotherapies for obesity: A systematic review. Pharmacological Reviews, 2025. PMID: 39952695. doi:10.1124/pharmrev.123.001045
This is not personal medical advice. See our medical disclaimer and editorial standards.
Licensed physician and clinical AI specialist. Founder and Editor-in-Chief of ZayedMD, a physician-led medical publication covering clinical AI, neurology, metabolic health, and evidence-based patient guidance.
